NOVO.B.DK

378.9

+1.99%↑

COLO.B.DK

569.8

-0.14%↓

GMAB.DK

2,089

+3.01%↑

HLUNB.DK

45.28

+1.8%↑

AMBUB.DK

107.2

+3.38%↑

NOVO.B.DK

378.9

+1.99%↑

COLO.B.DK

569.8

-0.14%↓

GMAB.DK

2,089

+3.01%↑

HLUNB.DK

45.28

+1.8%↑

AMBUB.DK

107.2

+3.38%↑

NOVO.B.DK

378.9

+1.99%↑

COLO.B.DK

569.8

-0.14%↓

GMAB.DK

2,089

+3.01%↑

HLUNB.DK

45.28

+1.8%↑

AMBUB.DK

107.2

+3.38%↑

NOVO.B.DK

378.9

+1.99%↑

COLO.B.DK

569.8

-0.14%↓

GMAB.DK

2,089

+3.01%↑

HLUNB.DK

45.28

+1.8%↑

AMBUB.DK

107.2

+3.38%↑

NOVO.B.DK

378.9

+1.99%↑

COLO.B.DK

569.8

-0.14%↓

GMAB.DK

2,089

+3.01%↑

HLUNB.DK

45.28

+1.8%↑

AMBUB.DK

107.2

+3.38%↑

Search

Zealand Pharma A-S

Abierto

512.4 1.67

Resumen

Variación precio

24h

Actual

Mínimo

502.2

Máximo

517.8

Métricas clave

By Trading Economics

Ingresos

7.9B

7.6B

Ventas

9.1B

9.1B

P/B

Media del Sector

4.918

35.739

BPA

105.61

Margen de beneficio

83.335

Empleados

424

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+25.15% upside

Dividendos

By Dow Jones

Próximas Ganancias

13 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

8.7B

32B

Apertura anterior

510.73

Cierre anterior

512.4

Zealand Pharma A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

12 mar 2025, 09:23 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 dic 2024, 09:22 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 mar 2025, 16:34 UTC

Principales Noticias

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mar 2025, 08:18 UTC

Charlas de Mercado

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Comparación entre iguales

Cambio de precio

Zealand Pharma A-S Esperado

Precio Objetivo

By TipRanks

25.15% repunte

Estimación a 12 meses

Media 270.582 DKK  25.15%

Máximo 270.568 DKK

Mínimo 270.568 DKK

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zealand Pharma A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
help-icon Live chat